CinCor Pharma: A small pharma’s journey to acquisition

In this episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD. Marc tells Jonah all about CinCor and its unique approach to hypertension, how the AstraZeneca deal came about, and what happens next.

The company’s technology lands at AstraZeneca at the end of a long journey that started with Roche Diagnostics and travelled through Cincinatti incubator CinRx. At CinCor, the company was able to unlock the value of this therapy for treatment-resistant hypertension.

Marc describes the latest stage of this journey in some detail and talks about why AstraZeneca was interested in the company and why his team decided the time was right to sell, including some setbacks along the way, with the company overcoming some disappointing – but ultimately misleading – study results.

Finally, he looks ahead to the future of CinCor and its lead asset, and gives his advice to other companies looking to pull off a similarly successful exit.

You can listen to episode 80 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series - in iTunes, Spotify, acast, Stitcher, and Podbean.